TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 163 full-time employees. The company went IPO on 2024-08-20. The firm is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.
02410.HK stock price ended at $13.56 on 金曜日, after dropping 1.17%
On the latest trading day Jan 16, 2026, the stock price of 02410.HK fell by 1.17%, dropping from $13.94 to $13.56. During the session, the stock saw a volatility of 4.03%, with prices oscillating between a daily low of $13.40 and a high of $13.94. On the latest trading day, the trading volume for 02410.HK decreased by 1.1M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 2.0M shares were traded, with a market value of approximately $5.0B.